Controlled Trial of Cervical Cancer Screening Frequency Among Human Papillomavirus Vaccinated Women II: Cervical Pre-Cancer End-Points by Specific Non-Vaccine HPV Types

We conducted a controlled trial among 5626 early adolescent women vaccinated in 2007–2009 against human papillomavirus (HPV) types 16/18 to evaluate the impact of high-intensity versus low-intensity cervical screening, respectively at ages 22/25/28 and 28 years with squamous-cell intraepithelial lesions (SILs) as the end-point. Over the 16-year follow-up, most of the cytologically and/or histologically confirmed low-grade and high-grade SILs were associated with non-vaccine-targeted, medium oncogenicity HPV types 33/35/52/58 belonging to clade A9. The low-intensity cervical screening was non-inferior to the high-intensity screening in the identification of these lesions. Possibly, the transition from cervical infections with vaccine-covered HPV types to infections with non-vaccine-covered HPV types contributes to more manageable occurrence of the screen-detected cervical lesions. Reduction of cervical screening among vaccinated women to a minimum may be warranted to balance the harm—benefit ratio of screening.